For the quarter ending 2026-03-31, AWHL had -$411K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 676 | -3,369 | -4,892 | -4,519 |
| Non-cash lease expense | 9 | 11 | 36 | 122 |
| Depreciation and amortization | 40 | 38 | 50 | 24 |
| Stock-based compensation expense | 42 | 376 | 36 | 119 |
| Change in fair value of warrant liabilities | -3,110 | 1,595 | 4,309 | -297 |
| Change in fair value of march 2025 convertible notes | - | 0 | 0 | -170 |
| Loss upon issuance of march 2025 convertible notes carried at fair value | - | 0 | 0 | 1,198 |
| Loss on impairment and disposal of property and equipment | -1 | 0 | 0 | -1 |
| Financing expense for entering into 2025 lincoln park equity line of credit | - | 412 | - | - |
| Accounts receivable | 217 | -110 | 39 | 288 |
| Prepaid expenses and other assets | -120 | 429 | -245 | -426 |
| Inventories | 36 | -24 | 9 | -53 |
| Accounts payable | 731 | -574 | 68 | -430 |
| Accrued liabilities | 5 | -670 | 138 | -616 |
| Other liabilities | 1,380 | 495 | -154 | -459 |
| Net cash used in operating activities | -359 | -1,981 | -212 | -4,836 |
| Purchase of property and equipment | - | 8 | 8 | 0 |
| Purchase of intangible assets | - | 0 | 385 | - |
| Net cash used in investing activities | - | -8 | -393 | 0 |
| Proceeds from issuance of common stock-Two Thousand Twenty Four Direct Offering | - | - | - | 0 |
| Principal repayment of decd loan | 59 | 59 | 58 | 116 |
| Proceeds from issuance of common stock-Two Thousand Twenty Four At The Market Offering Agreement | - | 0 | 0 | 3,484 |
| Payment of stock issuance costs-Two Thousand Twenty Four At The Market Offering Agreement | - | 0 | 147 | - |
| Proceeds from issuance of common stock-Two Thousand Twenty Five Private Placement Offering | - | 0 | 2,949 | - |
| Payment of stock issuance costs-Two Thousand Twenty Five Private Placement Offering | - | 6 | 134 | - |
| Proceeds from issuance of common stock from exercise of warrants | - | 0 | 112 | - |
| Proceeds from march 2025 convertible notes | - | 0 | 0 | 1,366 |
| Proceeds from issuance of common stock-Equity Line Of Credit Agreement | - | 25 | - | 0 |
| Payment of stock issuance costs-Two Thousand Twenty Four Direct Offering | - | - | - | 0 |
| Payment of stock issuance costs | - | - | - | 147 |
| Proceeds from 2025 equity purchase agreement | -18 | - | 0 | 25 |
| Net cash provided by financing activities | -52 | -65 | 2,869 | 4,612 |
| Net decrease in cash and cash equivalents | -411 | -2,054 | 2,264 | -224 |
| Cash and cash equivalents , beginning of year | 1,755 | 3,809 | 1,769 | - |
| Cash and cash equivalents , end of year | 1,344 | 1,755 | 3,809 | - |
Aspira Women's Health Inc. (AWHL)
Aspira Women's Health Inc. (AWHL)